Dow Jumps 210 Points On Vaccine News From AstraZeneca Unlisted Video
3 years ago
22
Astrazeneca
S&P 500 INDEX-CBOE
NASDAQ COMPOSITE INDEX
DOW JONES INDUSTRIAL AVERAGE INDEX
Articles
Vaccination
Virology
COVID-19 Vaccine
COVID-19 Pandemic In The United States
Presidency Of Donald Trump
S&P 500 INDEX - CBOE
On Monday, US stocks rose.
AstraZeneca said its COVID-19 vaccine candidate demonstrated an average efficacy rate of 70%.
This is the third COVID-19 vaccine said to have surpassed the Food and Drug Administration's requirement of 50% effectiveness.
S&P 500: 3,580.82, up 0.7%
Dow Jones industrial average: 29,473.41, up 0.7% (210 points)
Nasdaq composite: 11,929.04, up 0.6%
Loading comments...
-
0:22
Newsy
3 years agoAstraZeneca COVID-19 Vaccine Trial Participant Dies
2.92K2 -
0:59
Newsy
4 years agoAstraZeneca Pauses COVID-19 Vaccine Trial
11.1K1 -
0:30
Newsy
3 years agoAstrazeneca Resumes Phase 3 Coronavirus Vaccine Trial
1.49K4 -
1:20
Newsy
3 years agoFDA Widens Investigation Into AstraZeneca COVID-19 Vaccine
7521 -
0:54
Newsy
3 years agoUnited Kingdom Starts Accelerated Review Of AstraZeneca Vaccine
1.59K -
0:21
WFTS
3 years agoAstraZeneca, Oxford say their vaccine is up to 90% effective
101 -
1:26
WFTS
4 years agoAstraZeneca COVID-19 vaccine trial paused after one illness
1.21K1 -
0:55
WFTX
3 years agoPromising Phase 3 trial results from COVID-19 vaccine
124 -
0:38
Newsy
3 years agoAstraZeneca Coronavirus Vaccine Trials Remain Stalled In The U.S.
346 -
3:47
KGTV
3 years agoStock markets respond to vaccine news
28